speb/financial-data huggingface dataset:
ZYME income_statement (annual, 2023-12-31) — Normalized EBITDA: -119517000.00
ZYME income_statement (annual, 2023-12-31) — Normalized Income: -117494644.66
ZYME cash_flow (annual, 2023-12-31) — Operating Cash Flow: -118324000.00
ZYME cash_flow (annual, 2023-12-31) — Operating Gains Losses: -31000.00
ZYME income_statement (annual, 2023-12-31) — Operating Income: -138007000.00
ZYME income_statement (annual, 2023-12-31) — Operating Revenue: 76012000.00
ZYME balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 70115997.00
ZYME balance_sheet (annual, 2023-12-31) — Other Current Assets: 19122000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 2530000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -6603000.00
ZYME income_statement (annual, 2023-12-31) — Other Gand A: 48100000.00
ZYME income_statement (annual, 2023-12-31) — Other Income Expense: -894000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 25284000.00
ZYME cash_flow (annual, 2023-12-31) — Other Non Cash Items: 630000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 7566000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 1609000.00
ZYME income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 291000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Payable: 729000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Properties: 29503000.00
ZYME balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 216770000.00
ZYME balance_sheet (annual, 2023-12-31) — Payables: 8023000.00
ZYME balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 39120000.00
ZYME balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 6153000.00
ZYME balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
ZYME income_statement (annual, 2023-12-31) — Pretax Income: -119242000.00
ZYME cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 5826000.00
ZYME balance_sheet (annual, 2023-12-31) — Properties: 0.00
ZYME cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -1603000.00
ZYME cash_flow (annual, 2023-12-31) — Purchase Of Investment: -553249000.00
ZYME cash_flow (annual, 2023-12-31) — Purchase Of PPE: -2474000.00
ZYME balance_sheet (annual, 2023-12-31) — Receivables: 19477000.00
ZYME income_statement (annual, 2023-12-31) — Reconciled Depreciation: 17305000.00
ZYME cash_flow (annual, 2023-12-31) — Repayment Of Debt: -21000.00
ZYME cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: 0.00
ZYME income_statement (annual, 2023-12-31) — Research And Development: 143619000.00
ZYME balance_sheet (annual, 2023-12-31) — Retained Earnings: -677437000.00
ZYME income_statement (annual, 2023-12-31) — Salaries And Wages: 22300000.00
ZYME cash_flow (annual, 2023-12-31) — Sale Of Investment: 350073000.00
ZYME income_statement (annual, 2023-12-31) — Selling General And Administration: 70400000.00
ZYME balance_sheet (annual, 2023-12-31) — Share Issued: 70115997.00
ZYME income_statement (annual, 2023-12-31) — Special Income Charges: 0.00
ZYME cash_flow (annual, 2023-12-31) — Stock Based Compensation: 8102000.00
ZYME balance_sheet (annual, 2023-12-31) — Stockholders Equity: 464806000.00
ZYME balance_sheet (annual, 2023-12-31) — Tangible Book Value: 427506000.00
ZYME income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -5644.66
ZYME income_statement (annual, 2023-12-31) — Tax Provision: -568000.00
ZYME income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
ZYME balance_sheet (annual, 2023-12-31) — Total Assets: 580880000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Capitalization: 464806000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Debt: 26722000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 464806000.00
ZYME income_statement (annual, 2023-12-31) — Total Expenses: 214019000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 116074000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 167954000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 60311000.00
ZYME income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -138053000.00
ZYME balance_sheet (annual, 2023-12-31) — Total Tax Payable: 1811000.00
ZYME income_statement (annual, 2023-12-31) — Total Unusual Items: -1185000.00
ZYME income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -1185000.00
ZYME cash_flow (annual, 2023-12-31) — Unrealized Gain Loss On Investment Securities: 667000.00
ZYME balance_sheet (annual, 2023-12-31) — Working Capital: 357163000.00
ZYME cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 0.00
ZYME cash_flow (quarterly, 2024-09-30) — Common Stock Issuance: 0.00
ZYME balance_sheet (quarterly, 2024-09-30) — Held To Maturity Securities: 77667000.00
ZYME income_statement (quarterly, 2024-09-30) — Impairment Of Capital Assets: 0.00
ZYME balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 77667000.00
ZYME cash_flow (quarterly, 2024-09-30) — Issuance Of Capital Stock: 0.00
ZYME cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: -3000.00
ZYME cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: -20624000.00
ZYME cash_flow (quarterly, 2024-09-30) — Net Issuance Payments Of Debt: -3000.00
ZYME cash_flow (quarterly, 2024-09-30) — Net Long Term Debt Issuance: -3000.00
ZYME cash_flow (quarterly, 2024-09-30) — Net Other Financing Charges: -92000.00
ZYME cash_flow (quarterly, 2024-09-30) — Other Non Cash Items: 0.00
ZYME balance_sheet (quarterly, 2024-09-30) — Other Payable: 833000.00
ZYME cash_flow (quarterly, 2024-09-30) — Repayment Of Debt: -3000.00
ZYME income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
ZYME income_statement (annual, 2024-12-31) — +Operating Expense: 196121000.00
ZYME income_statement (annual, 2024-12-31) — +Total Revenue: 76304000.00
ZYME balance_sheet (annual, 2024-12-31) — Accounts Payable: 3903000.00
ZYME balance_sheet (annual, 2024-12-31) — Accounts Receivable: 55815000.00
ZYME balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -17830000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -17830000.00
ZYME balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 152249000.00
ZYME cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 4496000.00
ZYME cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 4496000.00
ZYME cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 17287000.00
ZYME cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 0.00
ZYME income_statement (annual, 2024-12-31) — Average Dilution Earnings: 140000.00
ZYME income_statement (annual, 2024-12-31) — Basic Average Shares: 75846681.00
ZYME income_statement (annual, 2024-12-31) — Basic EPS: -1.62
ZYME cash_flow (annual, 2024-12-31) — Beginning Cash Position: 157557000.00
ZYME cash_flow (annual, 2024-12-31) — Capital Expenditure: -3066000.00
ZYME balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 18506000.00
ZYME balance_sheet (annual, 2024-12-31) — Capital Stock: 1023806000.00
ZYME balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 66103000.00
ZYME balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 225776000.00
ZYME balance_sheet (annual, 2024-12-31) — Cash Equivalents: 31483000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Cash Equivalents: 31483000.00
ZYME balance_sheet (annual, 2024-12-31) — Cash Financial: 34620000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Cash Financial: 34620000.00
ZYME cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -20438000.00
ZYME cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 38756000.00
ZYME cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -110058000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Account Payable: 14321000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Income Tax Payable: -1682000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -8313000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 3555000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Payable: 12639000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 12639000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -2489000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Receivables: -36359000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Tax Payable: -1682000.00
ZYME cash_flow (annual, 2024-12-31) — Change In Working Capital: -30967000.00
ZYME cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -36359000.00
ZYME cash_flow (annual, 2024-12-31) — Changes In Cash: -91740000.00
ZYME balance_sheet (annual, 2024-12-31) — Common Stock: 1023806000.00
ZYME balance_sheet (annual, 2024-12-31) — Common Stock Equity: 338768000.00
ZYME cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
ZYME cash_flow (quarterly, 2024-12-31) — Common Stock Issuance: 0.00
ZYME cash_flow (annual, 2024-12-31) — Common Stock Payments: -30051000.00
ZYME cash_flow (quarterly, 2024-12-31) — Common Stock Payments: -9427000.00
ZYME balance_sheet (annual, 2024-12-31) — Construction In Progress: 0.00
ZYME balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 0.00
ZYME balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 47199000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 47199000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Assets: 300451000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 2740000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 2740000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 25588000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 25588000.00
ZYME balance_sheet (annual, 2024-12-31) — Current Liabilities: 88294000.00
ZYME cash_flow (annual, 2024-12-31) — Deferred Income Tax: 691000.00
ZYME cash_flow (annual, 2024-12-31) — Deferred Tax: 691000.00
ZYME cash_flow (annual, 2024-12-31) — Depreciation: 6697000.00
ZYME cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 11193000.00
ZYME cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 11193000.00
ZYME income_statement (annual, 2024-12-31) — Diluted Average Shares: 75878738.00
ZYME income_statement (annual, 2024-12-31) — Diluted EPS: -1.62
ZYME income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -122555000.00
ZYME income_statement (annual, 2024-12-31) — EBIT: -119817000.00
ZYME income_statement (annual, 2024-12-31) — EBITDA: -108624000.00
ZYME cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 286000.00
ZYME cash_flow (annual, 2024-12-31) — End Cash Position: 66103000.00
ZYME cash_flow (annual, 2024-12-31) — Financing Cash Flow: -20438000.00
ZYME cash_flow (annual, 2024-12-31) — Free Cash Flow: -113124000.00
ZYME income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 776000.00
ZYME income_statement (quarterly, 2024-12-31) — Gain On Sale Of Security: 597000.00
ZYME balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -6952000.00
ZYME income_statement (annual, 2024-12-31) — General And Administrative Expense: 61500000.00
ZYME balance_sheet (annual, 2024-12-31) — Goodwill: 12016000.00
ZYME balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 16592000.00
ZYME balance_sheet (annual, 2024-12-31) — Gross PPE: 52146000.00
ZYME income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 17287000.00
ZYME income_statement (quarterly, 2024-12-31) — Impairment Of Capital Assets: 0.00
ZYME cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 3179000.00
ZYME balance_sheet (annual, 2024-12-31) — Income Tax Payable: 128000.00
ZYME income_statement (annual, 2024-12-31) — Interest Income: 19941000.00
ZYME income_statement (annual, 2024-12-31) — Interest Income Non Operating: 19941000.00
ZYME balance_sheet (annual, 2024-12-31) — Invested Capital: 338768000.00
ZYME cash_flow (annual, 2024-12-31) — Investing Cash Flow: 38756000.00
ZYME balance_sheet (annual, 2024-12-31) — Investments And Advances: 98428000.00
ZYME cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
ZYME cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: 0.00
ZYME balance_sheet (annual, 2024-12-31) — Leases: 15190000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Leases: 15190000.00
ZYME balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 15766000.00
ZYME balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 15766000.00
ZYME cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -14000.00
ZYME cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: -2000.00
ZYME balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 6959000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 6959000.00
ZYME cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -30051000.00
ZYME cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: -9427000.00
ZYME cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: -1481000.00
ZYME income_statement (annual, 2024-12-31) — Net Income: -122695000.00
ZYME income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -122695000.00
ZYME income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -122695000.00
ZYME income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -122695000.00
ZYME income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -122695000.00
ZYME cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -122695000.00
ZYME income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -122695000.00
ZYME cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -1075000.00
ZYME income_statement (annual, 2024-12-31) — Net Interest Income: 19941000.00
ZYME cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 41822000.00
ZYME cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -14000.00
ZYME cash_flow (quarterly, 2024-12-31) — Net Issuance Payments Of Debt: -2000.00
ZYME cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -14000.00
ZYME cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: -2000.00
ZYME income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 19941000.00
ZYME cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -174000.00
ZYME cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: 0.00
ZYME balance_sheet (annual, 2024-12-31) — Net PPE: 34316000.00
ZYME cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -1991000.00
ZYME balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 322176000.00
ZYME balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 4385000.00
ZYME balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 19368000.00
ZYME balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 14607000.00
ZYME balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 4385000.00
ZYME balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 4761000.00
ZYME income_statement (annual, 2024-12-31) — Normalized EBITDA: -92113000.00
ZYME income_statement (annual, 2024-12-31) — Normalized Income: -109651310.00
ZYME cash_flow (annual, 2024-12-31) — Operating Cash Flow: -110058000.00
ZYME cash_flow (annual, 2024-12-31) — Operating Gains Losses: -1481000.00
ZYME income_statement (annual, 2024-12-31) — Operating Income: -119817000.00
ZYME income_statement (annual, 2024-12-31) — Operating Revenue: 76304000.00
ZYME balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 68964319.00
ZYME balance_sheet (annual, 2024-12-31) — Other Current Assets: 18860000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 1264000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 1264000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -6952000.00
ZYME income_statement (annual, 2024-12-31) — Other Gand A: 35400000.00
ZYME income_statement (annual, 2024-12-31) — Other Income Expense: -16729000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 4576000.00
ZYME cash_flow (annual, 2024-12-31) — Other Non Cash Items: -1878000.00
ZYME cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: 0.00
ZYME balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 8919000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 895000.00
ZYME income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -218000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Properties: 29997000.00
ZYME balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 159673000.00
ZYME balance_sheet (annual, 2024-12-31) — Payables: 5281000.00
ZYME balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 52480000.00
ZYME balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 6222000.00
ZYME balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 6222000.00
ZYME balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
ZYME income_statement (annual, 2024-12-31) — Pretax Income: -116611000.00
ZYME cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 9787000.00
ZYME balance_sheet (annual, 2024-12-31) — Properties: 0.00
ZYME balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
ZYME cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -1075000.00
ZYME cash_flow (annual, 2024-12-31) — Purchase Of Investment: -283743000.00
ZYME cash_flow (annual, 2024-12-31) — Purchase Of PPE: -1991000.00
ZYME balance_sheet (annual, 2024-12-31) — Receivables: 55815000.00
ZYME income_statement (annual, 2024-12-31) — Reconciled Depreciation: 11193000.00
ZYME cash_flow (annual, 2024-12-31) — Repayment Of Debt: -14000.00
ZYME cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: -2000.00
ZYME cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -30051000.00
ZYME cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: -9427000.00
ZYME income_statement (annual, 2024-12-31) — Research And Development: 134621000.00
ZYME balance_sheet (annual, 2024-12-31) — Retained Earnings: -830335000.00
ZYME income_statement (annual, 2024-12-31) — Salaries And Wages: 26100000.00
ZYME cash_flow (annual, 2024-12-31) — Sale Of Investment: 325565000.00
ZYME income_statement (annual, 2024-12-31) — Selling General And Administration: 61500000.00
ZYME balance_sheet (annual, 2024-12-31) — Share Issued: 68964319.00
ZYME income_statement (annual, 2024-12-31) — Special Income Charges: -17287000.00
ZYME income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
ZYME cash_flow (annual, 2024-12-31) — Stock Based Compensation: 17792000.00
ZYME balance_sheet (annual, 2024-12-31) — Stockholders Equity: 338768000.00
ZYME balance_sheet (annual, 2024-12-31) — Tangible Book Value: 322176000.00
ZYME income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -3467310.00
ZYME income_statement (annual, 2024-12-31) — Tax Provision: 6084000.00
ZYME income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
ZYME balance_sheet (annual, 2024-12-31) — Total Assets: 463091000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Capitalization: 338768000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Debt: 18506000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 338768000.00
ZYME income_statement (annual, 2024-12-31) — Total Expenses: 196121000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 124323000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 162640000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 36029000.00
ZYME income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -137110000.00
ZYME balance_sheet (annual, 2024-12-31) — Total Tax Payable: 1378000.00
ZYME income_statement (annual, 2024-12-31) — Total Unusual Items: -16511000.00
ZYME income_statement (quarterly, 2024-12-31) — Total Unusual Items: 597000.00
ZYME income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -16511000.00
ZYME income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 597000.00
ZYME cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
ZYME balance_sheet (annual, 2024-12-31) — Working Capital: 212157000.00
ZYME income_statement (quarterly, 2025-03-31) — +Operating Expense: 52738000.00
ZYME income_statement (quarterly, 2025-03-31) — +Total Revenue: 27110000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 5223000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 24594000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 154216000.00
ZYME cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 1617000.00
ZYME cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 1617000.00
ZYME income_statement (quarterly, 2025-03-31) — Average Dilution Earnings: -177000.00
ZYME income_statement (quarterly, 2025-03-31) — Basic Average Shares: 75171020.00
ZYME income_statement (quarterly, 2025-03-31) — Basic EPS: -0.30
ZYME cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 66103000.00
ZYME cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -338000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 18460000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Capital Stock: 1030128000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 76204000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 265287000.00
ZYME cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 1316000.00
ZYME cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 12182000.00
ZYME cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -3407000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -21219000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: -1000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -814000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -2093000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Payable: -21220000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -21220000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 2872000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Receivables: 31219000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: -1000.00
ZYME cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 9964000.00
ZYME cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 31219000.00
ZYME cash_flow (quarterly, 2025-03-31) — Changes In Cash: 10091000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Common Stock: 1030128000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 324967000.00
ZYME cash_flow (quarterly, 2025-03-31) — Common Stock Payments: 0.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 29635000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Assets: 306467000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 3258000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 3258000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 23495000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 23495000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 65103000.00
ZYME cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -410000.00
ZYME cash_flow (quarterly, 2025-03-31) — Deferred Tax: -410000.00
ZYME cash_flow (quarterly, 2025-03-31) — Depreciation: 1688000.00
ZYME cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 3305000.00
ZYME cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 3305000.00
ZYME income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 75226387.00
ZYME income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.30
ZYME income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -22813000.00
ZYME income_statement (quarterly, 2025-03-31) — EBIT: -22140000.00
ZYME income_statement (quarterly, 2025-03-31) — EBITDA: -18835000.00
ZYME cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 10000.00
ZYME cash_flow (quarterly, 2025-03-31) — End Cash Position: 76204000.00
ZYME cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 1316000.00
ZYME cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -3745000.00
ZYME income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -2000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -6406000.00
ZYME income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 17000000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Goodwill: 12016000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 15378000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Gross PPE: 33408000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 56324000.00
ZYME cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 387000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 127000.00
ZYME income_statement (quarterly, 2025-03-31) — Interest Expense: 0.00
ZYME income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 0.00
ZYME income_statement (quarterly, 2025-03-31) — Interest Income: 3424000.00
ZYME income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 3424000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Invested Capital: 324967000.00
ZYME cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 12182000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 56324000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 56324000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 15202000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 15202000.00
ZYME cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
ZYME cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -32000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income: -22636000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -22636000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -22636000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -22636000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -22636000.00
ZYME cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -22636000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -22636000.00
ZYME cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -322000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Interest Income: 3424000.00
ZYME cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 12520000.00
ZYME income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 3424000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Net PPE: 33408000.00
ZYME cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -16000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 309589000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 4849000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 19422000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 14607000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 4849000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 4815000.00
ZYME income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -18835000.00
ZYME income_statement (quarterly, 2025-03-31) — Normalized Income: -22636000.00
ZYME cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -3407000.00
ZYME cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -32000.00
ZYME income_statement (quarterly, 2025-03-31) — Operating Income: -25628000.00
ZYME income_statement (quarterly, 2025-03-31) — Operating Revenue: 27110000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 69584811.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 16586000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 707000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -6406000.00
ZYME income_statement (quarterly, 2025-03-31) — Other Gand A: 9500000.00
ZYME income_statement (quarterly, 2025-03-31) — Other Income Expense: 49000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 3362000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 9096000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 828000.00
ZYME income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 49000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Properties: 33408000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 189083000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Payables: 5355000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 34990000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2653000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
ZYME income_statement (quarterly, 2025-03-31) — Pretax Income: -22140000.00
ZYME cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 1316000.00
ZYME cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -322000.00
ZYME cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -34032000.00
ZYME cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -16000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Receivables: 24594000.00
ZYME income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 3305000.00
ZYME cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: 0.00
ZYME income_statement (quarterly, 2025-03-31) — Research And Development: 35738000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -852971000.00
ZYME income_statement (quarterly, 2025-03-31) — Salaries And Wages: 7500000.00
ZYME cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 46552000.00
ZYME income_statement (quarterly, 2025-03-31) — Selling General And Administration: 17000000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Share Issued: 69584811.00
ZYME cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 6402000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 324967000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 309589000.00
ZYME income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
ZYME income_statement (quarterly, 2025-03-31) — Tax Provision: 496000.00
ZYME income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
ZYME balance_sheet (quarterly, 2025-03-31) — Total Assets: 425522000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 324967000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Debt: 18460000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 324967000.00
ZYME income_statement (quarterly, 2025-03-31) — Total Expenses: 52738000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 100555000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 119055000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 35452000.00
ZYME income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -25613000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 132000.00
ZYME income_statement (quarterly, 2025-03-31) — Total Unusual Items: -2000.00
ZYME income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -2000.00
ZYME balance_sheet (quarterly, 2025-03-31) — Working Capital: 241364000.00
ZYME income_statement (quarterly, 2025-06-30) — +Operating Expense: 49349000.00
ZYME income_statement (quarterly, 2025-06-30) — +Total Revenue: 48726000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 32000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 2631000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 109243000.00
ZYME cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 1606000.00
ZYME cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 1606000.00
ZYME income_statement (quarterly, 2025-06-30) — Average Dilution Earnings: -1000.00
ZYME income_statement (quarterly, 2025-06-30) — Basic Average Shares: 75337168.00
ZYME income_statement (quarterly, 2025-06-30) — Basic EPS: 0.03
ZYME cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 76204000.00
ZYME cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -884000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 18678000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Capital Stock: 1082257000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 98253000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 281379000.00
ZYME cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 1319000.00
ZYME cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 8745000.00
ZYME cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 12073000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -7105000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: -26000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -818000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -19684000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Payable: -7131000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -7131000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 5490000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Receivables: 21989000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: -26000.00
ZYME cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -154000.00
ZYME cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 21989000.00
ZYME cash_flow (quarterly, 2025-06-30) — Changes In Cash: 22137000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Common Stock: 1082257000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 334506000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 25888000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Assets: 296130000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 3586000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 3586000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 3811000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 3811000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 38502000.00
ZYME cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 115000.00
ZYME cash_flow (quarterly, 2025-06-30) — Deferred Tax: 115000.00
ZYME cash_flow (quarterly, 2025-06-30) — Depreciation: 1608000.00
ZYME cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 3214000.00
ZYME cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 3214000.00
ZYME income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 77378449.00
ZYME income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.03
ZYME income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2316000.00
ZYME income_statement (quarterly, 2025-06-30) — EBIT: -623000.00
ZYME income_statement (quarterly, 2025-06-30) — EBITDA: 2591000.00
ZYME cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -88000.00
ZYME cash_flow (quarterly, 2025-06-30) — End Cash Position: 98253000.00
ZYME cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 1319000.00
ZYME cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 11189000.00
ZYME income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -613000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -6340000.00
ZYME income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 14900000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Goodwill: 12016000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 14061000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Gross PPE: 32574000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Held To Maturity Securities: 51996000.00
ZYME income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 0.00
ZYME cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 196000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 102000.00
ZYME income_statement (quarterly, 2025-06-30) — Interest Income: 3426000.00
ZYME income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 3426000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Invested Capital: 334506000.00
ZYME cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 8745000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 51996000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 51996000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 15092000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 15092000.00
ZYME cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: 710000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income: 2317000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2317000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2317000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2317000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2317000.00
ZYME cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 2317000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2317000.00
ZYME cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -370000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Interest Income: 3426000.00
ZYME cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 9629000.00
ZYME income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 3426000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Net PPE: 32574000.00
ZYME cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -514000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 320445000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 4769000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 19457000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 14607000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 4769000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 4850000.00
ZYME income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3204000.00
ZYME income_statement (quarterly, 2025-06-30) — Normalized Income: 2801270.00
ZYME cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 12073000.00
ZYME cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 710000.00
ZYME income_statement (quarterly, 2025-06-30) — Operating Income: -623000.00
ZYME income_statement (quarterly, 2025-06-30) — Operating Revenue: 48726000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 75416049.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 12120000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 697000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -6340000.00
ZYME income_statement (quarterly, 2025-06-30) — Other Gand A: 7900000.00
ZYME income_statement (quarterly, 2025-06-30) — Other Income Expense: -621000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 2045000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 8855000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 828000.00
ZYME income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -8000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Properties: 32574000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 183126000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Payables: 144000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 26032000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 4376000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
ZYME income_statement (quarterly, 2025-06-30) — Pretax Income: 2131000.00
ZYME cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 1384000.00
ZYME cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -370000.00
ZYME cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -70147000.00
ZYME cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -514000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Receivables: 2631000.00
ZYME income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 3214000.00
ZYME income_statement (quarterly, 2025-06-30) — Research And Development: 34449000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -850654000.00
ZYME income_statement (quarterly, 2025-06-30) — Salaries And Wages: 7000000.00
ZYME cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 79776000.00
ZYME income_statement (quarterly, 2025-06-30) — Selling General And Administration: 14900000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Share Issued: 75416049.00
ZYME income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
ZYME cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 5871000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 334506000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 320445000.00
ZYME income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -128730.00
ZYME income_statement (quarterly, 2025-06-30) — Tax Provision: -186000.00
ZYME income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
ZYME balance_sheet (quarterly, 2025-06-30) — Total Assets: 408385000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 334506000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Debt: 18678000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 334506000.00
ZYME income_statement (quarterly, 2025-06-30) — Total Expenses: 49349000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 73879000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 112255000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 35377000.00
ZYME income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -674000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 112000.00
ZYME income_statement (quarterly, 2025-06-30) — Total Unusual Items: -613000.00
ZYME income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -613000.00
ZYME balance_sheet (quarterly, 2025-06-30) — Working Capital: 257628000.00
ZYME income_statement (quarterly, 2025-09-30) — +Operating Expense: 49678000.00
ZYME income_statement (quarterly, 2025-09-30) — +Total Revenue: 27614000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1305000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 29352000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 111489000.00
ZYME cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 648000.00
ZYME cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 648000.00
ZYME cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 0.00
ZYME balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 47427000.00
ZYME income_statement (quarterly, 2025-09-30) — Average Dilution Earnings: -168000.00
ZYME income_statement (quarterly, 2025-09-30) — Basic Average Shares: 75767778.00
ZYME income_statement (quarterly, 2025-09-30) — Basic EPS: -0.26
ZYME cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 98253000.00
ZYME cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -410000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 18904000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Capital Stock: 1101097000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 64834000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 251933000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 23498000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Cash Financial: 41336000.00
ZYME cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -2452000.00
ZYME cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 368000.00
ZYME cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -31412000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 3341000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Income Tax Payable: 915000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -872000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -614000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Payable: 4256000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 4256000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 3267000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Receivables: -26721000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Tax Payable: 915000.00
ZYME cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -20684000.00
ZYME cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -26721000.00
ZYME cash_flow (quarterly, 2025-09-30) — Changes In Cash: -33496000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Common Stock: 1101097000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 320064000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 28182000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Assets: 291712000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 3400000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 3400000.00